

RPG LIFE SCIENCES LIMITED						
Regd. Office: RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400 030.						
(Rs. in Lakhs)						
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2018						
Particulars	Quarter ended			Nine months ended		Year ended
	31-12-2018	30-09-2018	31-12-2017	31-12-2018	31-12-2017	31-03-2018
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Revenue from Operations	9,097	9,050	9,566	26,136	26,368	34,714
2 Other Income	2	6	51	38	66	98
3 Total Income	9,099	9,056	9,617	26,174	26,434	34,812
4 Expenses						
(a) Cost of Materials Consumed	1,459	1,194	2,253	4,164	5,043	7,195
(b) Purchases of Stock-in-Trade	1,132	957	1,515	3,304	3,571	4,935
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	336	1,126	(434)	1,212	183	(669)
(d) Excise Duty Paid on sale of goods	-	-	-	-	319	319
(e) Employee Benefits Expense	2,394	2,386	2,313	7,002	6,527	9,014
(f) Finance Costs	99	105	93	308	297	380
(g) Depreciation and Amortisation Expense	386	381	360	1,138	1,066	1,434
(h) Other Expenses	2,568	2,597	2,717	7,753	7,831	10,168
Total Expenses	8,374	8,746	8,817	24,881	24,837	32,776
5 Profit before tax	725	310	800	1,293	1,597	2,036
6 Income tax expenses						
a. Current Tax	120	85	136	266	297	385
b. Deferred Tax	77	9	118	100	80	306
7 Profit for the period	528	216	546	927	1,220	1,345
8 Other Comprehensive Income						
(i) Items that will not be reclassified to Profit or Loss	(6)	(6)	(23)	(18)	(69)	(22)
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	2	2	-	6	-	8
Other Comprehensive Income Net of Tax	(4)	(4)	(23)	(12)	(69)	(14)
9 Total Comprehensive Income for the period	524	212	523	915	1,151	1,331
10 Paid-up Equity Share Capital (Face Value Rs. 8 each)	1,323	1,323	1,323	1,323	1,323	1,323
11 Other Equity						14,152
12 Earnings per Share (of Rs. 8 each) (not annualised):						
(a) Basic	3.19	1.31	3.30	5.61	7.38	8.13
(b) Diluted	3.19	1.31	3.30	5.61	7.38	8.13

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 05, 2019. The Statutory Auditors of the Company have conducted a 'Limited Review' of the results for the quarter and nine months ended December 31, 2018.
- The Company operates in only one reportable business segment i.e., Pharmaceuticals.
- The Government of India introduced the Goods and Services Tax (GST) with effect from 1st July 2017, consequently revenue from operations for the quarters ended 30th September 2018, 30th September 2017 and 30th June 2018; for six months ended 30th September 2018 is net of GST. However revenue for all other periods presented is inclusive of excise duty, where applicable. The Net Revenue from operations (Net of GST/ Excise Duty) as applicable are stated below:

Particulars	Quarter ended			Nine months ended		Year ended
	31-12-2018	30-09-2018	31-12-2017	31-12-2018	31-12-2017	31-03-2018
Revenue from Operations	9,097	9,050	9,566	26,136	26,368	34,714
Less: Excise Duty	-	-	-	-	319	319
Net Revenue from operations	9,097	9,050	9,566	26,136	26,049	34,395

- Effective April 1, 2018, the Company has adopted Ind AS 115 'Revenue from contracts with customers'. Based on the assessment done by the management, there is no material impact on the revenue recognised during the period.

For RPG Life Sciences Limited

Yugal Sikri
Managing Director
Mumbai, February 05, 2019